RAD51C and inflammatory breast carcinoma: Since our study showed that 31% of IBC patients had somatic and/or germline (pathogenic or likely pathogenic) mutations in genes involved in the homologous recombination repair (HRR) pathway (BRCA1, BRCA2, PALB2, RAD51C, BARD1, ATM), these patients would benefit from PARP inhibitors.